Tax Reform in This Election Year: It's Not Likely
Which Credit Card Rewards Does the IRS Care About?In the current choppy/consolidating (or perhaps worse) market, pharmaceutical companies and selected biotechs garner attention as defensive plays, and among these Celgene is worth an evaluation.
Celgene Corporation (Nasdaq: CELG) develops and markets drugs to treat cancer, immunological disorders, and other diseases. The company's research concentrates on small molecule compounds that inhibit tumor necrosis factor alpha (TNFa) production or aberrant estrogen production, or that may regulate kinases and ligases (enzymes).
Analysts really like the revenue growth rate for Revlimid, which received U.S. FDA approval in 2005, and treats a malignant blood disease called MDS. In 2006, Revlimid also received FDA approval to treat myeloma. Mainstay Thalomid, which treats bone marrow cancer, rounds-out an impressive one-two signature drug duo.
Celgene Corporation (Nasdaq: CELG) develops and markets drugs to treat cancer, immunological disorders, and other diseases. The company's research concentrates on small molecule compounds that inhibit tumor necrosis factor alpha (TNFa) production or aberrant estrogen production, or that may regulate kinases and ligases (enzymes).
Analysts really like the revenue growth rate for Revlimid, which received U.S. FDA approval in 2005, and treats a malignant blood disease called MDS. In 2006, Revlimid also received FDA approval to treat myeloma. Mainstay Thalomid, which treats bone marrow cancer, rounds-out an impressive one-two signature drug duo.
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
